Filing summary
Issuer discrepancy: The request identifies HYPERION DEFI, INC., but the supplied Form 10-Q is for Eyenovia, Inc. (Nasdaq: EYEN), for the quarter ended March 31, 2019. This summary reflects the supplied filing.
Business context and reporting period
Eyenovia is a clinical-stage ophthalmic biopharmaceutical company developing microdose therapies using its Optejet delivery technology. It reported results for the three months ended March 31, 2019, with comparative results for the first quarter of 2018. The company had not generated product revenue or achieved profitability.
Management reported positive Phase III results for MicroStat; FDA acceptance of an investigational new drug application for a planned Phase III MicroPine trial; and plans to proceed with MicroTears registration activities in 2019. The filing also describes FDA feedback on Phase III requirements for MicroProst.
Key financial metrics
| Metric | Q1 2019 / March 31, 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $4.01 million | $2.09 million |
| General and administrative expense | $1.94 million | $1.34 million |
| Total operating expenses | $5.95 million | $3.43 million |
| Net loss | $5.93 million | $3.43 million |
| Basic and diluted loss per share | $0.50 | $0.45 |
| Cash used in operating activities | $5.90 million | $2.39 million |
| Cash and cash equivalents | $14.32 million | $19.73 million at December 31, 2018 |
| Working capital | $12.4 million | Prior-period comparable value not stated in the provided text |
| Debt | None outstanding | None outstanding at December 31, 2018 |
Margins are not meaningful because the company reported no product revenue. Stock-based compensation was $1.03 million in Q1 2019, including $609,322 from accelerated vesting of options. Cash provided by financing was $484,000, from stock-option exercises; there were no investing cash flows. Cash declined $5.41 million during the quarter.
Material changes versus the prior comparable period
- Net loss increased by approximately $2.50 million; operating expenses rose 73% year over year.
- R&D expense increased 91%, primarily due to higher contracted clinical and nonclinical services, supplies, additional personnel, and stock-based compensation.
- G&A expense increased 45%, reflecting higher payroll, public-company costs, and travel and entertainment.
- Operating cash use increased by approximately $3.51 million. Q1 2018 financing included IPO proceeds; Q1 2019 financing did not.
- Cash fell from $19.73 million at year-end 2018 to $14.32 million at March 31, 2019. The accumulated deficit reached $42.45 million.
Outlook, risks, contingencies and unusual items
- Management said cash on hand was expected to fund operating and capital requirements for at least 12 months from the filing date. It anticipated needing additional capital thereafter; inability to raise funds could require reduced costs and curtailed R&D.
- Management expected R&D and G&A expenses to increase as development advances, staffing grows, and public-company compliance costs continue.
- Key risks include clinical and regulatory outcomes, commercialization prospects, access to future financing, competition, and the possibility that actual results differ from forward-looking statements.
- Five executive employment agreements entered into in February 2019 provide severance benefits; estimated aggregate salary severance is approximately $419,000 for qualifying termination without a change-in-control event, or approximately $1.68 million following a qualifying corporate transaction, plus specified health-benefit reimbursement.
- The filing reports related-party consulting, lease, and R&D service arrangements. It recorded $320,140 of Q1 2019 R&D expense for services from a company owned by the VP of R&D; Senju, a related party, had earned no royalties because there had been no commercial sales in Asia.
- No legal proceedings were reported. Management concluded disclosure controls were effective at a reasonable assurance level and reported no material Q1 change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Eyenovia, Inc., not HYPERION DEFI, INC.
- Track cash burn, clinical spending, and the timing and terms of any future financing against management’s stated 12-month cash runway.
- Verify progress and regulatory milestones for MicroStat, MicroPine, MicroProst, and MicroTears.
- Review the effect of option exercises, stock-based compensation, and potential dilution; 1,618,346 potentially dilutive shares were excluded from diluted loss per share as anti-dilutive.
- Monitor related-party transactions and executive severance commitments.